Skip to main content

Novartis Ag (NVS-N) Quote - Press Releases

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Price Quote as of

More stories below advertisement

Latest Press Releases

Global Esophageal Cancer Drugs Market 2019 Industry, Share, Demands, Size, Trends, Key Players, Growth, Gross Margin, Revenue, Value Chain, Innovation, and Forecast Analysis till 2025
- KD Market Insights - Mon Feb 17, 6:48AM CST
KD Market Insights - CMTX
Mon Feb 17, 6:48AM CST
KDMI offers a six-year forecast for the between 2019 and 2025. By value, the Esophageal Cancer Drugs market is anticipated to flourish at a significant CAGR during the forecast period i.e. 2020 and 2025. This report presents the market drivers and industry trends globally across five regions: North America, Europe, Asia Pacific, Latin America & Middle East & Africa, which impacts the current nature and future status of the Esophageal Cancer Drugs market over the forecast period.
Novartis receives EC Approval for Beovu(R), a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
- Globe Newswire - Mon Feb 17, 5:11AM CST
Globe Newswire - CMTX
Mon Feb 17, 5:11AM CST
- Beovu (brolucizumab) is the only anti-VEGF treatment approved in Europe for wet AMD that offers the option to start eligible patients on three-month dosing intervals immediately after the loading phase1
Carrols Restaurant Group, Inc. Names Markus Hartmann as General Counsel
- BusinessWire - Fri Feb 14, 6:00AM CST
BusinessWire - CMTX
Fri Feb 14, 6:00AM CST
Carrols Restaurant Group, Inc. ("Carrols" or the "Company") (Nasdaq: TAST) today announced that it has appointed Markus Hartmann as the Company's Vice President and General Counsel effective February 18, 2020.
China Medical System (867.HK) Armed against Short Selling! The Biggest CSO Took Control of Full Industrial Chain
- JCN Newswire - Fri Feb 14, 3:48AM CST
JCN Newswire - CMTX
Fri Feb 14, 3:48AM CST
The short-selling company Blue Orca Capital would not have expected that its confrontation with China Medical System Holdings Limited ("China Medical System") actually helped the company. The confrontation allowed investors and the whole pharmaceutical industry in China to see the biggest CSO has quietly reached the end of its transformation into a new empire that has established full control over an industrial chain, from sales and marketing to production and quality, and has jumped from the domestic market to a company driven by global R&D innovative resources.
Monofocal IOLs Market Trends 2020: Drivers, Strategies, Segmentation Application, Technology & Market Analysis Research Report to 2025
- Stockestic - Thu Feb 13, 7:02AM CST
Stockestic - CMTX
Thu Feb 13, 7:02AM CST
An analysis of Global has been provided within the latest report launched by Big Market Research that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over the forecast period. Furthermore, the report provides an in-depth statistical overview in terms of trends outlining the geographical opportunities and contributions by prominent industry share contenders.
Cataract Surgery Devices Market Enhancement in Medical Sector 2020 : Abbott Laboratories(NYS:ABT), Novartis AG(OTC:NVSEF), Carl Zeiss Meditec AG
- Xherald - Thu Feb 13, 4:55AM CST
Xherald - CMTX
Thu Feb 13, 4:55AM CST
The Global report centers around giving admirably examined information on the Cataract Surgery Devices market request and supply proportion, the fare/import situation, and the present and future development proportion, cost and income just as an itemized and SWOT examination of key parts of the organizations on the territorial level including the volume utilization of the gadgets.
Ophthalmology Drugs and Devices Market Size Industry Leaders & New Revenue Pockets – 2027
- AmericaNewsHour - Wed Feb 12, 6:20AM CST
AmericaNewsHour - CMTX
Wed Feb 12, 6:20AM CST
Market Study Report Has Added A New Report On Ophthalmology Drugs And Devices Market That Provides A Comprehensive Review Of This Industry With Respect To The Driving Forces Influencing The Market Size. Comprising The Current And Future Trends Defining The Dynamics Of This Industry Vertical, This Report Also Incorporates The Regional Landscape Of Ophthalmology Drugs And Devices Market In Tandem With Its Competitive Terrain.
Topical Drug Delivery System Market Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast 2020 to 2027
- MENAFN - Wed Feb 12, 1:05AM CST
Wed Feb 12, 1:05AM CST
Stomach Cancer/Gastric Cancer Treatment Market to Reach USD 8.20 Billion by 2026; Rapid Adoption of PD-1 Inhibitors for Treating Gastric Cancers to Boost the Market: Fortune Business Insights(TM)
- GlobeNewswire - Tue Feb 11, 12:39AM CST
GlobeNewswire - CMTX
Tue Feb 11, 12:39AM CST
The global Stomach Cancer Treatment Market size is expected to reach USD 8.20 billion by 2026, exhibiting a CAGR of 15.3% during the forecast period. One of the major forces behind the rise of this market is the increasing prevalence of cancer in general and stomach cancer in particular worldwide. The GLOBOCAN 2018, which is a report on the global burden of cancer produced by the International Agency for Research on Cancer (IARC), estimates that in 2018, new cancer cases will be around 18 million and cancer-related deaths will be close to 9.6 million. Further, stomach cancer will account for 8.2% of the new cancer cases. Statistics released by the World Cancer Research Fund (WCRF) substantiate the IARC's findings. According to the WCRF, gastric cancer is the fourth mostly commonly diagnosed cancer worldwide, with 1 million new reported cases. As the incidence of stomach cancer increases across the globe, the demand for stomach cancer drugs will rise commensurately, spelling good news for this market.
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
- Globe Newswire - Tue Feb 11, 12:15AM CST
Globe Newswire - CMTX
Tue Feb 11, 12:15AM CST
- FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung cancer (NSCLC)1

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies